Your browser doesn't support javascript.
loading
A new antibiotic kills pathogens without detectable resistance.
Ling, Losee L; Schneider, Tanja; Peoples, Aaron J; Spoering, Amy L; Engels, Ina; Conlon, Brian P; Mueller, Anna; Schäberle, Till F; Hughes, Dallas E; Epstein, Slava; Jones, Michael; Lazarides, Linos; Steadman, Victoria A; Cohen, Douglas R; Felix, Cintia R; Fetterman, K Ashley; Millett, William P; Nitti, Anthony G; Zullo, Ashley M; Chen, Chao; Lewis, Kim.
Afiliación
  • Ling LL; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Schneider T; 1] Institute of Medical Microbiology, Immunology and Parasitology-Pharmaceutical Microbiology Section, University of Bonn, Bonn 53115, Germany [2] German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany.
  • Peoples AJ; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Spoering AL; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Engels I; 1] Institute of Medical Microbiology, Immunology and Parasitology-Pharmaceutical Microbiology Section, University of Bonn, Bonn 53115, Germany [2] German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany.
  • Conlon BP; Antimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA.
  • Mueller A; 1] Institute of Medical Microbiology, Immunology and Parasitology-Pharmaceutical Microbiology Section, University of Bonn, Bonn 53115, Germany [2] German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany.
  • Schäberle TF; 1] German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany [2] Institute for Pharmaceutical Biology, University of Bonn, Bonn 53115, Germany.
  • Hughes DE; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Epstein S; Department of Biology, Northeastern University, Boston, Massachusetts 02115, USA.
  • Jones M; Selcia, Ongar, Essex CM5 0GS, UK.
  • Lazarides L; Selcia, Ongar, Essex CM5 0GS, UK.
  • Steadman VA; Selcia, Ongar, Essex CM5 0GS, UK.
  • Cohen DR; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Felix CR; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Fetterman KA; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Millett WP; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Nitti AG; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Zullo AM; NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
  • Chen C; Antimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA.
  • Lewis K; Antimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA.
Nature ; 517(7535): 455-9, 2015 Jan 22.
Article en En | MEDLINE | ID: mdl-25561178
ABSTRACT
Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Farmacorresistencia Microbiana / Depsipéptidos / Viabilidad Microbiana / Antibacterianos / Mycobacterium tuberculosis Tipo de estudio: Prognostic_studies Idioma: En Revista: Nature Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Farmacorresistencia Microbiana / Depsipéptidos / Viabilidad Microbiana / Antibacterianos / Mycobacterium tuberculosis Tipo de estudio: Prognostic_studies Idioma: En Revista: Nature Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos